Condition
Systemic Sclerosis (Scleroderma)
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07182968Recruiting
Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
NCT00613171Phase 2CompletedPrimary
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
NCT00226889Phase 1TerminatedPrimary
Treatment of Early Systemic Sclerosis by Bosentan
Showing all 3 trials